

CVD escalation therapy for secondary prevention (update) committee meeting 3

Date: 30/3/2023

Location: Virtual via Zoom

Minutes: Final

Committee members present:	
Nigel Beckett	
Chris Clark	
Parijat De (Co-opted member)	Present for items 3-7
Aroon Hingorani (Co-opted member)	
Satwinder Kaur	Present for items 3-5
Paul Leeson	
Joseph Mills (Chair)	
Riyaz Patel (Topic adviser)	
David Preiss	
Eduard Shantsila	
Wayne Sunman	
Colin Wilkinson	

Expert witness:		
Andrew Black	Vice-Chair, NICE Indicator Advisory Committee and General Practitioner	Present for item 4 only

In attendance:		
Serena Carville	Associate Director/Guideline Lead	
Catrina Charlton	Guideline Commissioning Manager	
Alfredo Mariani	Technical Analyst (Economics)	
Edgar Masanga	Resource Impact Lead	
Patrick Muller	Technical Adviser, Methods and Economics	

4.0.03 DOC Cmte minutes

	Team	
Joanna Perkin	Medical Editor	
Eleanor Samarasekera	Senior Systematic Reviewer	
Amelia Unsworth	Senior Project Manager	
Melina Vasileiou	Technical Analyst	
David Wonderling	Head of Health Economics	

Observers:

Charlotte Fairclough	Technical Adviser, Quality standards & indicators team
David Hutchings	Chief Pharmaceutical Officer's Clinical Fellow
Lynne Kincaid	Senior Analyst, Data & Analytics team
Sharon Swain	Associate Director, GDT NGC

Apologies:

Beverley Bostock	Committee member
Hugh Gallagher	Committee member
Ruth Price	Committee member
Chakravarthi Rajkumar	Co-opted member
Lina Gulhane	Head of Information Specialists, GDT NGC

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 3rd meeting on CVD escalation therapy for secondary prevention.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included: review of the economic model structure, inputs and preliminary results for LDL-c.

2. Confirmation of matters under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matters under discussion were:

- lipid-lowering therapies for escalation of therapy for secondary prevention for

4.0.03 DOC Cmte minutes

people with CVD.

The Chair asked everyone to verbally declare any interests in addition to those previously declared.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Eduard Shantsila	Senior Clinical Lecturer in Primary Care and Mental Health, University of Liverpool	Attending the ESC Preventative Cardiology conference in Malaga on 14 April 2023 and that the organisers will fund his travel and accommodation costs as part of his role as secretary of the Primary Care and Risk Factor Management Section and for chairing several presentation sessions, 30.3.23.	Direct financial	Non-specific No action needed other than process of open declaration Reasonable attendance costs
Nigel Beckett	Consultant Physician in Ageing and Health, Guys and St Thomas' NHS Foundation Trust	Member of the Data & Safety Monitoring Board (DSMB) for REducing Cognitive decline and dementiA by Lowering blood pressure (RECALL) trial. This is a de-centralised clinical trial of an Investigational Medicinal Product (IMP) (phase 3-4) to investigate blood pressure lowering for the prevention of mild cognitive impairment and dementia in older adults, recruiting in Australia only, 30.3.23.	Direct non-financial professional and personal	Non-specific No action needed other than process of open declaration
Nigel Beckett	Consultant Physician in Ageing and Health, Guys and St Thomas' NHS Foundation Trust	Member of Data & Safety Monitoring Board (DSMB) for INTEGRITY (INTErgenerational intervention to Reduce frailTY) trial. This is randomised trial of intergenerational practice – purposely bringing older adults	Direct non-financial professional and personal	Non-specific No action needed other than process of open declaration

4.0.03 DOC Cmte minutes

		and young children together in a multifactorial intervention with a view to assess potential to reduce frailty, 30.3.23.		
Paul Leeson	Professor of Cardiovascular Medicine & Honorary Consultant Cardiologist, John Radcliffe Hospital, Oxford	Attending the ESC Preventive Cardiology meeting in Malaga 2023, and that his accommodation will be paid for by ESC. He will give a presentation on 'AI and databases' in relation to cardiovascular prevention and a recent position statement from the EAPC/ESC about hypertension in children that he co-authored, 30.3.23.	Direct financial	Non-specific No action needed other than process of open declaration Reasonable attendance costs
Joseph Mills	Consultant Cardiologist, Liverpool Heart & Chest Hospital	As part of his role as UK CVD Prevention Co-ordinator, attending the ESC Preventive Cardiology meeting in Malaga 2023. No funding of attendance costs, 30.3.23.	Direct non-financial professional and personal	Specific Declare and remain The topic is directly relevant, however the work of the coordinators does not pose a conflict to the topics under consideration in the guideline

ES declared that he will be attending the ESC Preventative Cardiology conference in Malaga on 14 April 2023 and that the organisers will fund his travel and accommodation costs as part of his role as secretary of the Primary Care and Risk Factor Management Section and for chairing several presentation sessions. The Chair and a senior member of the developer team did not consider that this interest posed a conflict with the topic under consideration and therefore no action was required.

4.0.03 DOC Cmte minutes

NB declared that he is a Member of the Data & Safety Monitoring Board (DSMB) for REducing Cognitive decline and dementiA by Lowering blood pressure (RECALL) trial. This is a de-centralised clinical trial of an Investigational Medicinal Product (IMP) (phase 3-4) to investigate blood pressure lowering for the prevention of mild cognitive impairment and dementia in older adults, recruiting in Australia only. NB also declared that he is a Member of the Data & Safety Monitoring Board (DSMB) for INTEGRITY (INTErgenerational intervention to Reduce frailTY) trial. This is a randomised trial of intergenerational practice – purposely bringing older adults and young children together in a multifactorial intervention with a view to assess potential to reduce frailty. The Chair and a senior member of the Developer’s team did not consider that these activities posed a conflict with the matters under discussion, therefore no further action was required.

PL declared that he is also attending the ESC Preventive Cardiology meeting in Malaga 2023, and that his accommodation will be paid for by ESC. He will give a presentation on ‘AI and databases’ in relation to cardiovascular prevention and a recent position statement from the EAPC/ESC about hypertension in children that he co-authored. The Chair and a senior member of the developer team did not consider that this interest posed a conflict with the topic under consideration and therefore no action was required.

The Chair declared that as part of his role as UK CVD Prevention Co-ordinator he is also attending the ESC Preventive Cardiology meeting in Malaga 2023, but that the organisers are not funding any of his attendance costs. A senior member of the developer team did not consider that this interest posed a conflict with the topic under consideration and therefore no action was required.

The Chair and a senior member of the Developer’s team reviewed the declarations of interest register for interests previously declared and noted that none posed a conflict with the matters under discussion, therefore no further action was required.

3. Health economic model: LDL-c structure, inputs and preliminary results

The Committee was given a presentation on the economic model structure, inputs and preliminary results for LDL-c.

4. NICE Indicators

The Committee was given an expert testimony by AB, Vice-Chair of the NICE Indicator Advisory Committee, on the background to producing an indicator for target cholesterol levels.

5. Discussion of the evidence

The Committee discussed the evidence presented.

4.0.03 DOC Cmte minutes

6. Minutes of the previous meeting
The minutes of the previous meeting were agreed as an accurate record.
7. Any other business
None

Date of next meeting: 11/5/23

Location of next meeting: Wandle 41+40, NICE offices, 2 Redman Place,
London E20 1JQ